Urinary 8‐iso‐prostaglandin F2α as a marker of metabolic risks in the general Japanese population: The ROAD study

Objective To determine whether 8‐iso‐prostaglandin F2α (8‐iso‐PGF2α) is a reliable biomarker of the accumulation of metabolic risks [e.g., overweight, hypertension, impaired glucose tolerance (IGT), and dyslipidemia]. Methods This was a cross‐sectional study of the baseline characteristics of a Japanese general population cohort study: Research on Osteoarthritis/Osteoporosis Against Disability (ROAD). Of 1,690 participants, 1,527 fulfilled all questionnaires and examinations. Free and conjugated urinary 8‐iso‐PGF2α levels and metabolic syndrome (MetS) components including blood pressure, HbA1c, total cholesterol, high‐density lipoprotein cholesterol (HDL‐C), and non‐HDL‐C were analyzed. The data were analyzed by ANCOVA, multiple regression analysis, and multinomial logistic analysis. Results 8‐iso‐PGF2α was significantly associated with HbA1c and significantly inversely associated with total cholesterol and non‐HDL‐C. Notably, IGT with an HbA1c cut‐off of 5.5% was significantly associated with 8‐iso‐PGF2α level in participants aged ≤50 years. Multinomial logistic regression analysis revealed 8‐iso‐PGF2α level was significantly associated with a greater number of MetS risks present; this association was stronger in younger participants. In participants aged ≥71 years, 8‐iso‐PGF2α was significantly associated with a greater number of MetS risks with higher IGT cut‐offs. Conclusions Urinary 8‐iso‐PGF2α can be a reliable marker of IGT and the accumulation of MetS risks, especially in younger people.